DFD-03 (0.1% Tazarotene), Twice-daily, Short-Contact Lotion Formulation, Showed Similar Pharmacokinetic Exposure to the Marketed Cream Product with Once-Daily Overnight Application. J of Skin. 2017;1(3.1):s46. doi:10.25251/skin.1.supp.45